Cormedix CRMD unveils its next round of earnings this Monday, August 10. Here is Benzinga's everything-that-matters guide for the earnings announcement.
Earnings and Revenue
Cormedix EPS is expected to be around $-0.14, according to sell-side analysts. Sales will likely be near $90.00 thousand. In the same quarter last year, Cormedix reported a loss per share of $-0.03 on sales of $35.27 thousand. If the company were to report in-line earnings when it publishes results Monday, quarterly profit would be down 366.67%. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | -0.23 | -0.24 | -0.25 | -0.21 |
| EPS Actual | -0.21 | -0.21 | -0.22 | -0.03 |
| Revenue Estimate | 170.00 K | 90.00 K | 190.00 K | 130.00 K |
| Revenue Actual | 74.05 K | 24.78 K | 59.53 K | 35.27 K |
Stock Performance
Over the past 52-week period, shares of Cormedix have declined 49.14%.
When looking at these results, it would make sense for shareholders to feel unsatisfied with these results.
Don't be surprised to see the stock move on comments made during its conference call. Cormedix is scheduled to hold the call at 16:30:00 ET and can be accessed here: http://public.viavid.com/player/index.php?id=141024
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
